NSCLC: age not a factor in survival benefit from ICIs

  • Elkrief A & al.
  • J Geriatr Oncol
  • 13 Jan 2020

  • curated by Kelli Whitlock Burton
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Survival benefit and immune-related adverse events (AEs) from immune checkpoint inhibitors (ICIs) do not differ between elderly and younger patients with NSCLC.

Why this matters

  • Treatment-related toxicities from chemotherapy are generally worse in older patients, but an association with age was not established for ICIs.

Study design

  • 381 patients with NSCLC were treated with ICIs.
  • Median follow-up was 19.3 months.
  • Funding: The Montreal Cancer Institute.

Key results

  • 67.5% of patients were aged
  • PFS was not significantly different between age groups (3.2 vs 4.3 months, respectively; P=.92).
  • OS was not significantly different between groups (13.7 vs 11.6 months; P=.29).
  • Rates of all-grade immune-related AEs were not significantly different between groups (57% vs 50%; P=.71).
  • After multivariable analysis, Eastern Cooperative Oncology Group Performance Status (ECOG) 0 vs ≥2 was associated with better PFS (HR, 2.58; P<.001 ecog vs was associated with better os p>

Limitations

  • Retrospective study.